The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider

Richard Geoffrey Vile, Dale Ando, David Kirn

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

The field of replication-selective oncolytic viruses (virotherapy) has exploded over the last 10 years. As with many novel therapeutic approaches, initial overexuberance has been tempered by clinical trial results with first-generation agents. Although a number of significant hurdles to this approach have now been identified, novel solutions have been proposed and improvements are being made at a furious rate. This article seeks to initiate a discussion of these hurdles, approaches to overcome them, and unique safety and regulatory issues to consider.

Original languageEnglish (US)
Pages (from-to)1062-1067
Number of pages6
JournalCancer Gene Therapy
Volume9
Issue number12
DOIs
StatePublished - Dec 1 2002

Fingerprint

Oncolytic Virotherapy
Oncolytic Viruses
Clinical Trials
Safety
Neoplasms
Therapeutics

Keywords

  • Cancer
  • Experimental therapeutics
  • Oncolytic
  • Virotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

The oncolytic virotherapy treatment platform for cancer : Unique biological and biosafety points to consider. / Vile, Richard Geoffrey; Ando, Dale; Kirn, David.

In: Cancer Gene Therapy, Vol. 9, No. 12, 01.12.2002, p. 1062-1067.

Research output: Contribution to journalArticle

@article{73cbc54f1d0b41d9b555a0b8fb2f71b8,
title = "The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider",
abstract = "The field of replication-selective oncolytic viruses (virotherapy) has exploded over the last 10 years. As with many novel therapeutic approaches, initial overexuberance has been tempered by clinical trial results with first-generation agents. Although a number of significant hurdles to this approach have now been identified, novel solutions have been proposed and improvements are being made at a furious rate. This article seeks to initiate a discussion of these hurdles, approaches to overcome them, and unique safety and regulatory issues to consider.",
keywords = "Cancer, Experimental therapeutics, Oncolytic, Virotherapy",
author = "Vile, {Richard Geoffrey} and Dale Ando and David Kirn",
year = "2002",
month = "12",
day = "1",
doi = "10.1038/sj.cgt.7700548",
language = "English (US)",
volume = "9",
pages = "1062--1067",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - The oncolytic virotherapy treatment platform for cancer

T2 - Unique biological and biosafety points to consider

AU - Vile, Richard Geoffrey

AU - Ando, Dale

AU - Kirn, David

PY - 2002/12/1

Y1 - 2002/12/1

N2 - The field of replication-selective oncolytic viruses (virotherapy) has exploded over the last 10 years. As with many novel therapeutic approaches, initial overexuberance has been tempered by clinical trial results with first-generation agents. Although a number of significant hurdles to this approach have now been identified, novel solutions have been proposed and improvements are being made at a furious rate. This article seeks to initiate a discussion of these hurdles, approaches to overcome them, and unique safety and regulatory issues to consider.

AB - The field of replication-selective oncolytic viruses (virotherapy) has exploded over the last 10 years. As with many novel therapeutic approaches, initial overexuberance has been tempered by clinical trial results with first-generation agents. Although a number of significant hurdles to this approach have now been identified, novel solutions have been proposed and improvements are being made at a furious rate. This article seeks to initiate a discussion of these hurdles, approaches to overcome them, and unique safety and regulatory issues to consider.

KW - Cancer

KW - Experimental therapeutics

KW - Oncolytic

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=0036903118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036903118&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700548

DO - 10.1038/sj.cgt.7700548

M3 - Article

C2 - 12522445

AN - SCOPUS:0036903118

VL - 9

SP - 1062

EP - 1067

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 12

ER -